18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The study objectives are as follows:
- To determine the safety of trial 18F-2-fluoro-2-deoxy-D-glucose, produced by a new
manufacturer, by surveillance for adverse events in patients having Positron Emission
Tomography Computed Tomography scans in a comprehensive program for indications
including, but not limited to, oncology, neurology, cardiac and infectious/inflammatory
processes.
- To determine the efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography
in differentiating benign from malignant solitary pulmonary nodules and calculate
sensitivity, specificity, and accuracy using pathologic confirmation as the gold
standard when available, or greater than 6 month follow up stability on Computed
Tomography scan when not.
The purpose of performing this clinical trial is to provide local access of
18F-2-fluoro-2-deoxy-D-glucose to the patients of Newfoundland and Labrador. This product has
been offered to patients over the last three years by transporting from facilities outside of
the province. There have been significant delays in access and in fact, times where
18F-2-fluoro-2-deoxy-D-glucose has not been available through this process. This has caused
delays and limitations of treatments for patients who rely on Positron Emission Tomography
Computed Tomography scans for diagnosis.